The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide.
about
Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in ChinaChemotherapeuticsAntitubercular therapy in patients with cirrhosis: challenges and optionsInfluence of genetic variants on toxicity to anti-tubercular agents: a systematic review and meta-analysis (protocol)Drug hepatotoxicity.An evaluation of the potential use of isoniazid, acetylisoniazid and isonicotinic acid for monitoring the self-administration of drugs.Antituberculosis drug-induced hepatotoxicity in childrenHigh-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo.Virtually Designed Triclosan-Based Inhibitors of Enoyl-Acyl Carrier Protein Reductase of Mycobacterium tuberculosis and of Plasmodium falciparum.Effectiveness of hepatoprotective drugs for anti-tuberculosis drug-induced hepatotoxicity: a retrospective analysis.Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis.Rifampicin exacerbates isoniazid-induced toxicity in human but not in rat hepatocytes in tissue-like culturesRisk factors for hepatotoxicity from antituberculosis drugs: a case-control study.Antituberculosis treatment-induced hepatotoxicity: role of predictive factors.Encapsulation of zinc-rifampicin complex into transferrin-conjugated silver quantum-dots improves its antimycobacterial activity and stability and facilitates drug delivery into macrophagesAntituberculosis drug-induced hepatotoxicity: concise up-to-date review.Pharmacogenomics of anti-TB drugs-related hepatotoxicity.A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases.Key factors of susceptibility to anti-tuberculosis drug-induced hepatotoxicity.Mechanism Investigation of Rifampicin-Induced Liver Injury Using Comparative Toxicoproteomics in Mice.Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.The role of metabolism in the hepatotoxicity of isoniazid and iproniazid.Killing of intracellular Mycobacterium tuberculosis by receptor-mediated drug delivery.Tuftsin-bearing liposomes as rifampin vehicles in treatment of tuberculosis in mice.Recurrent Drug-Induced Hepatitis in Tuberculosis-Comparison of Two Drug Regimens.Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used.Hypersensitivity hepatitis due to pyrazinamide.Control of meningococcal disease.Hydrazine production in children receiving isoniazid for the treatment of tuberculous meningitis.Monitoring and management of antituberculosis drug induced hepatotoxicity.A study of the effects of rifampicin on isoniazid metabolism in human volunteer subjects.Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis.Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens.Metabolomics approach discriminates toxicity index of pyrazinamide and its metabolic products, pyrazinoic acid and 5-hydroxy pyrazinoic acid.Lack of association between rifampicin plasma concentration and treatment-related side effects in osteoarticular infections
P2860
Q28478918-79B2BA27-528E-416B-858A-8386E0EF06D6Q30047670-E9EF3B05-7FF1-4BA8-8403-EF8D17DE99ABQ33626827-415DEC19-1763-4C02-BC8F-8DE7D08F90F4Q33901424-32050480-5E29-4A22-B203-573B3EFC9AB8Q34512476-5DE36C4F-C187-4E2F-90A5-C5387DB797EFQ34519190-57090E56-4B93-4445-8516-34F658CDCF49Q35096954-AAB20E3A-6770-4189-84EF-7DC2DBA79F9BQ35768944-AC53AFD7-10B5-49D8-9BB6-66D8A6EA8857Q36094825-17D7875B-B915-414E-950D-86E0C01473ACQ36190248-4F9A3AB5-9A17-4E59-8F54-2440230B7127Q36364005-D0B0FA95-ED6A-481F-9064-87D3256747BCQ36484652-7EC0B6CA-F3C6-41AB-AC8B-8BC5BDFF768CQ36512029-25E612E5-A4D8-4A4B-9267-62EA2FDC1F2FQ36680092-43E3530B-C2C9-429E-9184-C109D4DEA687Q36835620-141D6F91-553F-4096-BCFA-298673546731Q36998032-4BD7AEC9-9E04-4F6A-85C3-93963ECCD46FQ37096055-BBD69827-D5FE-41CD-BF09-22BC004093D0Q37278221-36230D93-173E-4BD5-903E-7F0940FA2FE0Q38360770-3C93A26D-9E8C-420D-A180-6675191AB796Q38431738-B1D68A32-8D45-4EC5-8C60-A4757B520C90Q38851516-5CA52B42-4546-46C1-9BCA-A32EF145174DQ39850167-8D96FDC8-39AD-45FA-8442-4197563A13CAQ40085618-C301B6EF-85A0-4202-9482-F78108CC0495Q40285325-F88A596C-9354-4BF9-A31E-947A407E3715Q41684440-ABDD48BC-646F-48AD-8EB0-A9B4106C6051Q42111332-D3A17C60-46E6-42A2-9E1D-DB226F6C849BQ42279691-E1A88E8A-8409-4ADB-8C6F-6D811D747062Q42881574-D09208C0-8E84-44A1-A3FE-6BE0D4940946Q43478913-E5E5E9EC-1595-4B39-AE41-D79CB09C045AQ44294261-BB5F1C9A-E104-4D76-9053-2C78488B2988Q44893020-EFB26250-5BE0-45ED-929E-6CF0AC80E1DBQ45199376-B5E1CBA1-AE0E-4A78-9509-7A3BD247A9C5Q46785668-A523BBD7-21E1-43C7-84EA-09897905A86BQ53743200-34A8BB8E-EEE6-44AB-B6A9-E1F3D6C4ACD2Q58856447-00264320-116C-4B11-817A-13E7A4D6B15F
P2860
The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide.
description
1978 nî lūn-bûn
@nan
1978年の論文
@ja
1978年論文
@yue
1978年論文
@zh-hant
1978年論文
@zh-hk
1978年論文
@zh-mo
1978年論文
@zh-tw
1978年论文
@wuu
1978年论文
@zh
1978年论文
@zh-cn
name
The hepatic toxicity of antitu ...... , rifampicin and pyrazinamide.
@en
The hepatic toxicity of antitu ...... , rifampicin and pyrazinamide.
@nl
type
label
The hepatic toxicity of antitu ...... , rifampicin and pyrazinamide.
@en
The hepatic toxicity of antitu ...... , rifampicin and pyrazinamide.
@nl
prefLabel
The hepatic toxicity of antitu ...... , rifampicin and pyrazinamide.
@en
The hepatic toxicity of antitu ...... , rifampicin and pyrazinamide.
@nl
P1433
P1476
The hepatic toxicity of antitu ...... , rifampicin and pyrazinamide.
@en
P2093
D J Girling
P356
10.1016/0041-3879(77)90022-8
P577
1978-03-01T00:00:00Z